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Larra´yoz, Ignacio M., Alonso Ferna´ndez-Nistal, Aitziber
Garce´s, Edurne Gorraitz, and M. Pilar Lostao. Characterization of
the rat Na/nucleoside cotransporter 2 and transport of nucleoside-
derived drugs using electrophysiological methods. Am J Physiol Cell
Physiol 291: C1395–C1404, 2006. First published July 12, 2006;
doi:10.1152/ajpcell.00110.2006.—The Na-dependent nucleoside
transporter 2 (CNT2) mediates active transport of purine nucleosides
and uridine as well as therapeutic nucleoside analogs. We used the
two-electrode voltage-clamp technique to investigate rat CNT2
(rCNT2) transport mechanism and study the interaction of nucleoside-
derived drugs with the transporter expressed in Xenopus laevis oo-
cytes. The kinetic parameters for sodium, natural nucleosides, and
nucleoside derivatives were obtained as a function of membrane
potential. For natural substrates, apparent affinity (K0.5) was in the low
micromolar range (12–34) and was voltage independent for hyperpo-
larizing membrane potentials, whereas maximal current (Imax) was
voltage dependent. Uridine and 2-deoxyuridine analogs modified at
the 5-position were substrates of rCNT2. Lack of the 2-hydroxyl
group decreased affinity but increased Imax. Increase in the size and
decrease in the electronegativity of the residue at the 5-position
affected the interaction with the transporter by decreasing both affinity
and Imax. Fludarabine and formycin B were also transported with
higher Imax than uridine and moderate affinity (102  10 and 66  6
M, respectively). Analysis of the pre-steady-state currents revealed
a half-maximal activation voltage of about 39 mV and a valence of
about 0.8. K0.5 for Na was 2.3 mM at 50 mV and decreased at
hyperpolarizing membrane potentials. The Hill coefficient was 1 at all
voltages. Direct measurements of radiolabeled nucleoside fluxes with
the charge associated showed a ratio of two positive inward charges
per nucleoside, suggesting a stoichiometry of two Na per nucleoside.
This discrepancy in the number of Na molecules that bind rCNT2
may indicate a low degree of cooperativity between the Na binding
sites.
two-electrode voltage clamp; concentrative nucleoside transport; pre-
steady-state currents
NUCLEOSIDE TRANSPORTERS are integral membrane proteins re-
sponsible for the uptake into the cells of natural nucleosides
and nucleoside-derived drugs used in anticancer and antiviral
therapies (5, 9, 12). In mammalian cells, these transporters
belong to two main transporter families: the equilibrative
nucleoside transporter (ENT) family, with broad substrate
selectivity, and the Na-dependent concentrative nucleoside
transporter (CNT) family (3, 9, 12). Three isoforms of the CNT
family have been cloned so far. They differ in their substrate
selectivity: CNT1 (N2 system) is pyrimidine preferring, CNT2
(N1 system) is purine preferring and also transports uridine,
and CNT3 (N3 system) shows broad selectivity, accepting both
pyrimidine and purine nucleosides (9, 10, 12). CNT1 and
CNT2 are located in the apical membrane of specialized
epithelial cells in small intestine, kidney, and liver and are also
expressed in brain, spleen, pancreas, and skeletal muscle. They
are responsible for the transepithelial flux of the nucleosides
and nucleoside drugs in combination with the ENT transporters
located at the basolateral membrane (3, 12).
Function of human CNT1 (hCNT1) and hCNT3 has been
extensively studied using electrophysiological techniques (15,
29, 30), and the substrate selectivity has been investigated for
these two isoforms as well as for human CNT2 in different
expression systems (8, 13–15, 21, 23, 27–30, 36). Previous
studies of substrate selectivity of rat CNT2 (rCNT2) have been
performed through inhibitory experiments (4, 16, 17) and with
electrophysiological methods at a fixed membrane potential
and substrate concentration (8). Nevertheless, a complete elec-
trophysiological characterization of rCNT2 has not been per-
formed yet. Therefore, the goal of the present work has been to
characterize rCNT2 function and obtain structural information
of its substrates by using the two-electrode voltage-clamp
technique applied to Xenopus laevis oocytes expressing the
transporter. We have directly determined the Na-nucleoside
stoichiometry and obtained the kinetic parameters (K0.5 and
Imax) for sodium, natural nucleosides, and relevant nucleoside-
derived drugs as a function of membrane potential. We also
have shown that rCNT2 exhibits pre-steady-state and Na-leak
currents. The structural requirements of rCNT2 substrates are
compared with those for hCNT2, suggesting that the rat could
be a good model for the studies of bioavailability of possible
drugs substrates of CNT2.
MATERIALS AND METHODS
Nucleosides. All nucleoside derivatives used in this study are
anticancer drugs, with the exception of formycin B, which is used in
the treatment of intestinal parasites, and 5-ethyl-2-deoxyuridine (Et-
dUrd), which has antiviral properties; 5-iodouridine (IUrd) and 2-
deoxyuridine (2dUrd) have been tested only in cell lines. Gemcita-
bine was purchased from the University Hospital (University of
Navarra, Pamplona, Spain). The rest of the nucleosides and deriva-
tives were obtained from Sigma (Alcobendas, Madrid, Spain).
Expression of rCNT2 in Xenopus laevis oocytes. Stage VI oocytes
from Xenopus laevis (Blades Biological, Cowden, UK) were obtained
as previously described (1). They were microinjected with 50 ng of
mRNA coding for the rCNT2 cloned from rat blood-brain barrier (16).
Rat CNT2 clone was kindly donated by Drs. W. M. Pardridge and
R. J. Boado (University of California, Los Angeles, CA). Oocytes
were maintained at 18°C in Barth’s medium [88 mM NaCl, 1 mM
KCl, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 2.4 mM
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NaHCO3, and 10 mM HEPES-Tris, pH 7.4] containing gentamycin
(50 mg/l). Experiments were performed at 22  1°C, 2–4 days after
injection.
Electrophysiology. The electrophysiology experiments were per-
formed using the two-microelectrode voltage-clamp method (1, 19,
24). The oocyte membrane potential was normally held at a potential
of 50 mV, and continuous current data were recorded using Axo-
scope V1.1.1.14 (Axon Instruments, Foster City, CA). To obtain the
current/voltage relationship, we applied 11 pulses of potential (test
potential) between 50 and 150 mV (20 mV decrement) for 100
ms using pCLAMP 6 software (Axon Instruments). The jump from
the holding potential to the test potential generates the “on” current,
and the return from the test potential to the holding potential, before
the next jump, generates the “off” current.
Steady-state kinetics. The apparent affinity constant (K0.5S ) and the
maximal current (ImaxS ) for saturating nucleoside concentrations were
obtained by fitting the steady-state currents (I) at each membrane
potential to the following equation:
I  ImaxS  Sn/K0.5S 	n Sn (1)
where [S] is the nucleoside concentration (7 concentrations from 2
M to 1 mM or from 50 M to 10 mM, depending on the nucleoside)
and n is the Hill coefficient, which was 1 for nucleoside kinetic
analysis. The fit was performed using the nonlinear fitting method in
SigmaPlot 8 (SPSS, Chicago, IL).
For Na activation experiments, saturating concentrations of uri-
dine (0.5 mM) were applied as NaCl concentration was varied
between 0 and 100 mM (0.1, 0.3, 0.5, 1, 2, 5, 20, and 100 mM),
substituting choline for Na. Uridine-dependent currents, at each
voltage, were fitted to Eq. 1, where, in this case, I is the uridine-
induced steady-state current, ImaxS is the maximal uridine current at
saturating Na concentrations, [S] is the Na concentration, K0.5S is
the sodium concentration at half-maximal current, and n is the Hill
coefficient.
Charge-to-nucleoside stoichiometry. To determine Na-to-nucleo-
side coupling stoichiometry, we directly compared unidirectional
[3H]adenosine uptake into voltage-clamped oocytes with the cotrans-
porter (substrate-induced) currents over the same time course in
individual oocytes (6, 15, 18). The nonspecific uptakes of [3H]aden-
osine in noninjected oocytes were 
1% of the rCNT2-specific up-
takes.
The oocyte was voltage-clamped at 50 mV and superfused with
100 mM Na medium. When the baseline was stable, 0.1 mM
[3H]adenosine was added to the Na solution at a final concentration
of 1.4 nCi/l. After 5–10 min, the nucleoside was removed from the
bathing solution, and the oocyte was superfused with Na buffer until
the current returned to the baseline. The oocyte was recovered from
the chamber, rinsed three times in ice-cold choline buffer, and solu-
bilized with 10% SDS for liquid scintillation counting. Uptake was
expressed as picomoles per oocyte. [3H]adenosine uptake in nonin-
jected oocytes was used to correct for endogenous adenosine uptake.
Adenosine-induced current was obtained as the difference between
baseline current and the current obtained after addition of adenosine
and was integrated to obtain total adenosine-dependent charge
(Qadenosine/adenosine). This charge was converted to its molar equiv-
alent using the Faraday’s constant.
Pre-steady-state currents. The pre-steady-state transient currents
observed after voltage steps are attributed to changes in the confor-
mation of the transporter (11, 19). These capacitive currents were
separated from the membrane capacitance and the steady-state con-
ductances using the fitted method (11). The transporter-mediated
charge at each membrane potential was then calculated by integrating
the transporter-transient currents with time. In most cases, the “off”
transient was analyzed. The charge-voltage (Q/V) relationships ob-
tained were fitted to the Boltzmann equation
Q  Qhyp	/Qmax 1/1 expzVt V0.5	F/RT (2)
where Qmax  Qdep  Qhyp, Qdep and Qhyp are the charges moved at
depolarizing and hyperpolarizing limits, respectively, z is the apparent
valence of the movable charge, Vt is the test potential, V0.5 is the
voltage at which the charge was equally distributed between depolar-
izing and hyperpolarizing limits, F is Faraday’s constant, R is the gas
constant, and T is the absolute temperature. The charge/voltage
relationship was obtained in the presence of different Na concentra-
tions (0.5, 1, 2, 5, 20, and 100 mM) and Qmax was calculated for each
concentration.
RESULTS
Kinetic parameters for natural nucleosides and derivatives.
We initially studied the substrate selectivity of rCNT2 in
oocytes clamped at 50 mV. As shown in Fig. 1, 1 mM
adenosine or uridine, natural substrates of the N1 transport
system, induced Na inward current, indicating that they are
substrates of rCNT2. Similarly, 1 mM of the two purine-
derived drugs fludarabine and formycin B and the uridine
derivative 5-fluoro-5-deoxyuridine (5-Dfur) also induced in-
ward current, demonstrating that they are transported. Unex-
pectedly, the cytidine derivative gemcitabine, substrate of the
N2 transport system (21), evoked inward current at 1 mM,
although it was very small. The higher currents induced by the
drugs compared with adenosine or uridine currents at saturat-
ing concentration (see K0.5 values in Fig. 3) suggest a higher
transport rate for the nucleoside derivatives. As happens in
other Na-dependent transporters, in the absence of substrate
and the presence of Na, rCNT2 shows a baseline current that
is not present when the oocyte is perfused with Na-free buffer
(Fig. 1D) or in noninjected oocytes (Fig. 1E); this current is
referred to as the Na-leak current through rCNT2.
We then studied the influence of the membrane potential on
the kinetic parameters of the natural substrates of rCNT2 and
the nucleoside-derived drugs. Figure 2A shows the Imax/V
relationship for uridine and inosine, another natural purine
nucleoside. Imax was voltage-dependent for both nucleosides,
increasing at hyperpolarizing membrane potentials, although
Imax for inosine was lower than that for uridine at all membrane
potentials (40% at 50 mV). K0.5 was voltage independent
at hyperpolarizing membrane potentials for the two nucleo-
sides and was also lower for inosine: at 50 mV, K0.5 was
8.0  0.3 and 20  3 M for inosine and uridine, respectively
(Fig. 2B). Figure 3 summarizes the K0.5 values and maximal
currents expressed as percentages of uridine current at saturat-
ing concentration for the natural nucleosides at 50 mV of
membrane potential. Considering the errors, apparent affinity
and Imax were similar for adenosine, guanosine, and uridine,
whereas inosine showed a slight increase in affinity and an
50% reduction in Imax. Thymidine and cytidine, substrates of
CNT1, can be also transported by rCNT2, although with lower
affinity and Imax (Fig. 3).
Imax was also voltage dependent for fludarabine (Fig. 2C),
5-Dfur, and formycin B (data not shown) and was higher than
Imax for uridine at all membrane potentials. Figure 2D shows
the K0.5/V relationship for fludarabine, 5-Dfur, and uridine.
K0.5 was voltage independent at hyperpolarizing membrane
potentials for the three nucleosides, being higher for fludara-
bine and 5-Dfur (4-fold and 1 order of magnitude, respec-
tively) than for uridine (see Fig. 4). K0.5 for formycin B was
C1396 ELECTROPHYSIOLOGICAL CHARACTERIZATION OF RCNT2
AJP-Cell Physiol • VOL 291 • DECEMBER 2006 • www.ajpcell.org
 o
n
 M
arch 12, 2012
ajpcell.physiology.org
D
ow
nloaded from
 
two to three times higher than for uridine (see Fig. 4). Another
six uridine derivatives with anticancer or antiviral activities
were tested and their kinetic parameters obtained as a function
of membrane potential. Figure 4 summarizes the K0.5 values
and maximal currents expressed as percentages of uridine
current at saturating concentration, at 50 mV of membrane
potential, for all tested derivatives.
Kinetic parameters for 5-fluorouridine (FUrd) are similar to
those for uridine (Fig. 4). However, IUrd showed much lower
affinity (18-fold) and an 30% decrease in Imax. In the case
of 2dUrd, there was an increase in K0.5 (6-fold) and Imax
(2.5-fold) (Fig. 2, E and F, and Fig. 4). Similarly, 5-fluoro-
2-deoxyuridine (FdUrd) showed increase in both kinetic pa-
rameters (7-fold for K0.5 and 20% for Imax). In 5-bromo-
2-deoxyuridine (BrdUrd), the presence of the bromine in the
5-position of the pyrimidine ring further decreased affinity (1
order of magnitude) and also diminished Imax (60%) (Fig. 4).
In thymidine, or 5-methyl-2-deoxyuridine, the methyl group
in the 5-position also decreased affinity and Imax in the same
degree as did the bromine atom (Fig. 3). When an ethyl group
is in the same position (EtdUrd), there is a further increase in
the affinity (1,127  287 M) and a decrease in Imax (80%)
compared with uridine kinetic parameters. Table 1 shows the
ratio Imax/K0.5, a measure of the transport efficiency, for all the
nucleosides and derivatives.
Since Imax for 2dUrd, 5-Dfur, and fludarabine was higher
than for uridine, these nucleoside derivatives were also tested,
at 1 mM concentration, in noninjected oocytes to check that
they did not induce any unspecific current. None of them
induced current in the control oocytes, indicating that the
higher currents evoked by those nucleosides in rCNT2-ex-
pressing oocytes were therefore solely due to the transporter.
Na activation kinetics. The rCNT2-mediated uridine-
evoked currents were measured as a function of Na concen-
tration at 10, 30, 50, 70, and 90 mV (Fig. 5). These
dose-response activation curves were fitted to Eq. 1 to obtain
the kinetic parameters for Na and the Hill coefficient. K0.5Na

decreased at hyperpolarizing membrane potentials from 6.5
Fig. 1. Interaction of nucleoside-derived
drugs with the rat Na-dependent concentra-
tive nucleoside transporter CNT2 (rCNT2).
A–C: rCNT2-expressing oocytes were held
at 50 mV of membrane potential and per-
fused with Na buffer in the absence of
substrate (open box), and current was con-
tinuously recorded (baseline current). A: ad-
dition of 1 mM adenosine (arrow) induced an
inward current of 20 nA. The oocyte was
then washed out with Na-free buffer (filled
box), which blocked the adenosine inward
current and the baseline current. After the
perfusion with Na buffer, the current re-
turned to baseline. The addition of 1 mM
fludarabine (F-Ara-A) induced an inward
current 2-fold higher than adenosine current,
indicating that it is transported. B: in a dif-
ferent oocyte the current induced by 1 mM
formycin B (For B) was also double the
current induced by 1 mM adenosine. Gem-
citabine (1 mM) induced a very small cur-
rent. C: 1 mM 5-fluoro-5-deoxyuridine (5-
Dfur) induced higher inward current than 0.5
mM uridine. D: a rCNT2-expressing oocyte
was held at 50 mV of membrane potential
and perfused with Na buffer in the absence
of substrate (open box), and current was
continuously recorded (baseline current).
The addition of 0.5 mM uridine induced an
inward current of 200 nA. This current and
the baseline current disappeared when the
oocyte was washed out with Na-free buffer
(filled box). The oocyte was then perfused
with Na buffer, and the baseline current
was restored; this current is referred to as the
Na-leak current. E: in a noninjected oocyte
from the same batch as the oocyte in D, no
uridine-induced current or Na-leak current
was obtained.
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mM at 10 mV to 0.25 mM at 90 mV (Fig. 5F). The Hill
coefficient was 1 for all membrane potentials (Fig. 5G).
To determine whether rCNT2 can be driven by H, as has
been shown for hCNT3 (30), we measured uridine-induced
current in choline buffer (absence of Na) at pH 6. No current
was observed, indicating that protons do not interact with
rCNT2 (data not shown). Experiments performed to resolve
whether K or Cl are involved in the nucleoside transport by
rCNT2 and contribute to generate the current revealed that
none of them altered the nucleoside-induced current (data not
shown). These results, therefore, indicate that the current
evoked by the nucleoside transport is due only to the cotrans-
port of Na.
rCNT2 stoichiometry. To determine charge/nucleoside stoi-
chiometry, we measured nucleoside-induced current and
[3H]adenosine uptake in the same rCNT2-expressing oocyte
over an equal time course. Figure 6, inset, shows an example of
an oocyte clamped at 50 mV and superfused with 100 mM
Na buffer, which produced the baseline current due to the
Na leak through the transporter. The addition of 0.1 mM
[3H]adenosine induced an inward current of 18 nA during 9
min of perfusion. When the nucleoside was removed from the
bath, the current returned to the baseline. The current was
integrated with time to determine the adenosine-dependent net
charge influx (Qadenosine) that was 9.9  106 C (coulomb) of
positive charge. This charge was converted to its molar equiv-
alent, 103 pmol, and compared with the [3H]adenosine uptake,
62 pmol, resulting in a charge-to-nucleoside ratio of 1.7 for this
oocyte. The same process was repeated with six oocytes. All
the data were fitted to a single regression line. For all oocytes
tested, the value of Qadenosine/adenosine uptake was 1.9  0.2
(Fig. 6), indicating that two net inward positive charges were
transported for every nucleoside cotransported, which is a
different result of coupling stoichiometry from that obtained
using the Hill coefficient (Fig. 5; see DISCUSSION).
Pre-steady-state currents. Similar to other cotransporters, in
the presence of Na and absence of substrate, rCNT2 shows
pre-steady-state currents that disappear upon addition of uri-
Fig. 2. Voltage dependence of apparent af-
finity (K0.5) and maximal current (Imax) for
uridine, inosine, fludarabine (F-Ara-A), 5-
Dfur, and 2-deoxyuridine (2dUrd). For each
nucleoside, K0.5 and Imax were obtained at
every membrane potential by fitting the
steady-state currents obtained at 7 different
concentrations (2–5,000 M) to Eq. 1 in
MATERIALS AND METHODS. A, C, and E: cur-
rent-voltage (Imax-V) curves for uridine and
inosine (A), fludarabine (C), or 2dUrd (E)
were obtained in 3 different oocytes. The
uridine curve corresponds to the inward cur-
rent at saturating uridine concentration (0.5
mM), which is equivalent to the Imax. B, D,
and F: K0.5-V curves for inosine (B), fludara-
bine and 5-Dfur (D), and 2dUrd (F) were
obtained. Uridine K0.5 is also shown for
comparison. The error bars correspond to the
error of the fit. Similar results were obtained
with oocytes from at least 3 different
batches.
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dine (Fig. 7) and are reduced by lowering the external Na
concentration (data not shown). Analysis of these currents
revealed a V0.5 of 39  5 mV (n  22), a z of 0.75  0.05
(n  15), and values of Qmax between 6 and 15 nC, depending
on the level of expression of the oocytes. Figure 7, inset, shows
the charge-voltage relationship of one oocyte expressing
rCNT2 for which V0.5 was 28  5 mV and Qmax was 14.4 
0.6 nC. As happens for other Na-coupled transporters, in
rCNT2 external Na influenced the V0.5. There was a shift in
V0.5 of 20 mV per e-fold change in Na concentration (from
5 to 100 mV). In agreement with the high affinity for Na,
Qmax did not change in a wide Na concentration range
(10–100 mM; data not shown).
DISCUSSION
In the present study we have reported a detailed electrophys-
iological characterization of the rat purine-preferring nucleo-
side transporter rCNT2 and shown the apparent affinity con-
stant and maximal current of a series of nucleoside-derived
drugs, contributing to the knowledge of the structural require-
ments for nucleoside derivatives transport by rCNT2. The
kinetic parameters for natural nucleosides reported presently
are in agreement with those obtained using uptake of radiola-
beled nucleosides in oocytes or cell lines expressing rCNT2
(16, 32) and similar to those for hCNT2 (13, 28, 33, 36), which
has a 81% identity with rCNT2.
Our results indicate that the pyrimidine-nucleosides thymi-
dine and cytidine, typical substrates of CNT1, are transported
by rCNT2, although with much lower affinity and maximal
current than uridine (Fig. 3). These findings explain why the
cytidine-derived drug gemcitabine produces some detectable
current (Fig. 1). Other authors (13, 17) have also shown that
thymidine is transported by rCNT2 and hCNT2. The kinetic
parameters of FUrd are similar to those for uridine. The
Fig. 3. Structure, apparent affinity constant, and
maximal current for natural nucleosides. K0.5 values
were calculated, at 50 mV membrane potential, by
fitting the currents generated by the substrate at 7
concentrations (2 M-10 mM) to Eq. 1 in MATERI-
ALS AND METHODS. Currents induced by saturating
nucleoside concentrations (Imax) are expressed as
percentages of the current generated by saturating
uridine concentration (0.5 mM) in the same oocyte.
Values are means  SE of 4–10 determinations.
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replacement of fluorine with iodine (IUrd) decreases apparent
affinity and maximal current (Fig. 4). These changes in recog-
nition and transportability may be due to both the bigger size
and the smaller electronegativity of the iodine. The same
values and changes in kinetic parameters for the two deriva-
tives occur in hCNT2 (13, 14, 36), which indicates that both
the rat and human isoforms of CNT2 are equally restrictive to
the residue size and electronegativity at the 5-position.
Unlike rCNT2, affinity and transport rate for 2dUrd in
hCNT2 are similar to those for uridine (13, 36). In accor-
dance to these results, Ki and current for 2-deoxyadenosine
are the same as those for adenosine in hCNT2 (13), whereas
current for this nucleoside is greater than that for adenosine
in rCNT2 (8). All these data indicate that the hydroxyl at
this position is more important for the rat than for the human
isoform.
The chemical structure of FdUrd is a “combination” of the
structure of the previous nucleosides. The lack of the hydroxyl
Table 1. Transport efficiency
Nucleoside Imax/K0.5
Adenosine 4.561.55
Inosine 4.422.13
Uridine 4.171.04
Guanosine 3.620.89
ForB 3.260.49
FUrd 2.810.63
F-A-Ara 1.880.36
2dUrd 1.570.50
FdUrd 0.640.15
5-Dfur 0.370.21
IUrd 0.150.03
BrdUrd 0.130.07
Thymidine 0.090.05
Cytidine 0.060.009
EtdUrd 0.020.007
Ratio of maximal current (Imax) to apparent affinity (K0.5) is a measure of
transport efficiency.
Fig. 4. Structure, apparent affinity constant, and
maximal current for nucleoside-derived drugs trans-
ported by rCNT2. K0.5 values were calculated, at
50 mV membrane potential, by fitting the currents
generated by the substrate at 7 concentrations (2
M-10 mM) to Eq. 1 in MATERIALS AND METHODS.
Imax induced by saturating nucleoside derivative
concentrations are expressed as percentages of the
current generated by saturating uridine concentra-
tion (0.5 mM) in the same oocyte. Values are
means  SE of 4–7 determinations. K0.5 value for
formycin B corresponds to 1 experiment, and its
error is the error of the fit of the experimental data
to Eq. 1. FUrd, 5-fluorouridine; IUrd, 5-iodouridine;
2dUrd, 2-deoxyuridine; FdUrd, 5-fluoro-2-de-
oxyuridine; BrdUrd, 5-bromo-2-deoxyuridine; Et-
dUrd, 5-ethyl-2-deoxyuridine; 5-Dfur, 5-fluoro-5-
deoxyuridine; F-Ara-A, fludarabine; For B, formy-
cin B.
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residue would increase Imax, as in 2dUrd, but the fluorine
would slightly decrease Imax as for FUrd. As a result, there is
an increase in maximal current, but not as large as that for
2dUrd. In hCNT2, affinity and maximal transport rate for
FdUrd would be expected to be similar to those for uridine, as
shown in one report (13). Recently, however, a Ki value for
FdUrd of 151  7 M was reported (36). This Ki is close to the
K0.5 we obtained for rCNT2 (188  34 M). Strikingly, other
authors (8) have not found any detectable current induced by
FdUrd in either rCNT2 or hCNT2.
The bigger size and smaller electronegativity of bromine
compared with fluorine may explain the decrease in affinity
and Imax in BrdUrd (Fig. 4). Likewise, in hCNT2 there is a
reduction in these parameters for BrdUrd of magnitude similar
to that in rCNT2 (13, 36).
The methyl group in the 5-position of thymidine affects the
kinetic parameters in the same degree as BrdUrd (Figs. 3 and
4). Although the methyl group is slightly smaller than the
bromine atom, it is a weak electron donor, which suggests that
the size of the substituent at the 5-position and its ability for
accepting electrons are important for recognition and transport
of the nucleoside. This is confirmed by the higher decrease in
both affinity and Imax for EtdUrd (Fig. 4). A similar decrease in
the affinity for these three uridine derivatives was found for
hCNT2 (13, 36).
In 5-Dfur, since the fluorine does not alter the K0.5 for
uridine and slightly decreases Imax, it is the absence of the
hydroxyl group in the 5-position that may explain the modi-
fication in the kinetic constants. These results indicate that this
position is not a strict requirement for the recognition and
transport by rCNT2. However, in hCNT2, 5-Dfur is trans-
ported with much lower affinity and current than uridine (36).
So far, all these data permit us to deduce the following
conclusions. The hydroxyl group at the 2- and 5-positions are
Fig. 5. Na activation curves at different
membrane potential (Vh). A–E: K0.5Na was ob-
tained by fitting the currents at each Na
concentration to Eq. 1 in MATERIALS AND
METHODS. Each curve corresponds to a single
representative rCNT2-expressing oocyte.
Similar results were obtained with oocytes
from 3 different batches. F: K0.5Na

as a func-
tion of Vh. G: Hill coefficient as a function
of Vh.
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not strictly required for transport by rCNT2, because although
the lack of either hydroxyl residue decreases the affinity, it
enhances the Imax. On the other hand, increase in the size and
decrease in the electronegativity of the residue at the 5-position
affect the interaction with the transporter by decreasing the
affinity and Imax. Therefore, a structure with a higher Imax/K0.5
ratio (Table 1) should be that with a substituent at the 5-posi-
tion of the same size or smaller than fluorine and more
electronegative than it. There are no elements that fulfill these
requirements, since fluorine is the most electronegative ele-
ment. Only oxygen, with a slightly bigger size and slightly
smaller electronegativity, could be a possible candidate.
The AOH at the 2-position is more important for binding
and transport for rCNT2 than for hCNT2. The AOH at the
5-position, however, is more important for the human isoform
than for the rat one. For both isoforms, the smaller the size of
the residue at the 5-position and the higher its ability for
accepting electrons, the better the affinity for the transporter.
The only difference between fludarabine (2-fluoro-9--D-
arabinofuranosyladenine) and adenosine is the presence of a
fluorine in the 2-position and that the hydroxyls at 2- and
3-positions are in trans configuration (Figs. 3 and 4). The
affinity of hCNT2 for 9--D-arabinofuranosyladenine is ap-
proximately threefold lower than for adenosine and even lower
for fludarabine (13). On the other hand, it has been demon-
strated that 9--D-arabinofuranosyladenine is transported by
rCNT2 with the same Imax as adenosine (8). From these data
and those in Fig. 4, it could be deduced that the decrease in
affinity of rCNT2 for fludarabine may be due to both the trans
configuration of the hydroxyl residues at the 2- and 3-
positions and the fluorine at the 2-position, whereas the in-
crease in Imax would be due to the presence of fluorine at that
position. Formycin B, an inosine derivative, is also transported
by murine CNT2 with a K0.5 similar to that reported presently
(25, 31).
Except for 2dUrd and 5-Dfur, the rest of molecules tested
in the present study are equally transported by rat and human
CNT2. According to the transport efficiency values in Table 1,
with the exception of maybe formycin B, FUrd, and fludara-
bine, the bioavailability of the derivatives tested is unlikely to
be due to transport by CNT2 in the presence of normal levels
of the natural nucleosides. The human isoform of CNT1 shows
a transport efficiency for FUrd, IUrd, 2dUrd, FdUrd, and
EtdUrd similar to that for uridine (Ref. 29 and unpublished
Fig. 7. Membrane current records of rCNT2. A: a rCNT2-expressing oocyte
was held at 50 mV and stepped to 11 test values between 50 and 150 mV
(20 mV decrement). In Na buffer and in the absence of uridine, the oocyte
showed pre-steady-state currents in response to step changes in the membrane
voltage and showed steady-state currents due to the Na leak through the
transporter. B: the addition of 1 mM uridine blocked the pre-steady-state
currents and caused an increase of the steady-state inward currents. Inset:
charge-voltage relationship for a representative oocyte expressing rCNT2. The
data (F) were obtained as described in MATERIALS AND METHODS and fitted to
the Boltzmann equation (solid line, Eq. 2) from which a V0.5 of 28  5 was
calculated.
Fig. 6. Charge-to-nucleoside stoichiometry for rCNT2. Inset: a representative
experiment showing 0.1 mM [3H]adenosine-induced inward current in a
rCNT2-expressing oocyte. Membrane potential was held at 50 mV, and the
oocyte perfused with Na buffer until a stable baseline current was recorded.
The addition of 0.1 mM [3H]adenosine increased the inward current to 18 nA
during 9 min of perfusion. Adenosine was then removed from the bath by
perfusing adenosine-free Na buffer, and the current returned to baseline. The
transported charge, Q, was calculated as the integral of the adenosine-depen-
dent current over the 9-min period and was 9.9  106 C. The [3H]adenosine
uptake in this oocyte was 62 pmol after subtraction of [3H]adenosine uptake,
over the same period, in a noninjected oocyte. Uptake of 0.1 mM [3H]ade-
nosine in the presence of 100 mM Na and the induced current were measured
for 5–10 min in 7 different oocytes as indicated in the inset. The adenosine-
dependent charge (Qadenosine) for each oocyte was plotted against the uptake of
adenosine in the same oocyte. The data were fitted to a linear regression with
a slope of 1.9  0.2 charges/adenosine.
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data from our laboratory), which suggests that CNT2 may be
less relevant than CNT1 in the transport of these drugs.
Moreover, hCNT3 also efficiently transports FUrd and FdUrd
and, to a lesser extent, fludarabine (27).
Among the nucleoside derivatives tested, some show de-
crease and others increase in Imax compared with uridine or
adenosine, similar to hCNT1 (2, 15, 23). Likewise, phenylglu-
cosides induce different maximal currents than the natural
sugars when they are transported by the Na/glucose cotrans-
porter SGLT1 (7, 20). These variations in transportability may
be explained by differences in the rate constant for the trans-
location of the Na-substrate-loaded cotransporter (7, 20) or
the release of the substrate inside the cell. Clearly, the steric
constraints, hydrogen bonds, and/or hydrophobic interactions
between the nucleoside and the binding site in the transporter
determine the affinity and maximal transport rate.
The previously reported apparent affinity constant of rCNT2
for Na, obtained by measuring adenosine flux in oocytes, was
2.4 mM (16). This value agrees with the present data at 30
mV (Fig. 5B). Therefore, rCNT2 has a high affinity for Na,
close to that reported for hCNT1 (15) and higher than that for
human or mouse CNT3 (27).
A Na:nucleoside stoichiometry of 1:1 has been reported for
rCNT2 and the N1 transport system from the analysis of the
Hill coefficient (16, 26). On the basis of Na activation curve
analysis, we have also obtained a Hill coefficient of 1. The Hill
coefficient is often used as an indirect method to estimate the
number of ligand molecules that are required to bind to a
transporter to generate transport. However, for a transporter
with more than one ligand binding site, “the Hill equation does
not reflect a physically possible reaction scheme; only under
the very specific condition of marked positive cooperativity
(the affinity of the binding has to be very asymmetric, with a
much lower affinity of binding for the first ligand molecule
than for the subsequent ligand molecules) does the Hill coef-
ficient accurately estimate the number of binding sites. The
Hill coefficient is best thought as an ‘interaction’ coefficient,
reflecting the extent of cooperativity among multiple ligand
binding sites” (34). Therefore, the Hill coefficient does not
always coincides with the stoichiometry obtained using direct
methods. We can find an example in SGLT3. Na-to-sugar
stoichiometry for pig SGLT3 (previously called pSGLT2) by
direct measurement was found to be 2:1 (6); in the same study
the authors reported a Hill coefficient of 1.5, but they quoted a
previous study from the same group in which, on the bases of
analysis of the Na Hill coefficient, it was suggested that the
pSGLT3 coupling was 1Na:1 sugar (22).
Knowing this limitation of the Hill equation, we wanted in
the present work to directly determine the relationship between
the inward current and the nucleoside uptake by rCNT2. The
results indicate that two inward charges are introduced into the
oocyte for each nucleoside that is transported, as occurs in
other members of the same family (15, 27, 35). Since H, K,
or Cl are not involved in the uridine-induced inward current,
these two charges may be attributable to Na. The discrepancy
between the Hill coefficient and the coupling ratio directly
obtained may indicate that the Na binding in rCNT2 has a
low degree of cooperatively between the two Na binding
sites. This stoichiometry would result in an increase in the
concentrative capacity of the transporter compared with a
stoichiometry of 1:1.
In relation to this result, using direct methods, we previously
reported a Na:nucleoside stoichiometry of 2:1 for hCNT1
(15), different from the 1:1 stoichiometry published by Smith
et al. (29). A possible explanation for the differences between
their results and ours in the stoichiometry could be related to
differences in the methodology.
Rat CNT2 shows pre-steady-state currents in the presence of
Na and absence of substrate that disappear after addition of
uridine to the solution and are reduced by lowering the external
Na concentration. As in hCNT1 and other cotransporter
families (11, 15, 19, 22, 24, 29), these currents reflect voltage-
dependent processes, due to charge movements, caused by
Na binding/dissociation and conformational changes in-
volved in the reorientation of the cotransporter in the mem-
brane. The existence of these currents and their study in depth
should be useful in future work to determine inhibitor binding
constants and obtain information about the partial reactions of
the transport cycle (11, 15, 19), and thereby acquire deeper
knowledge of the transport mechanism of the CNT transporter
family.
The bioavailability of the drugs, and therefore, the sensitiv-
ity or resistance to them, can be the result of the different
expression pattern of the nucleoside transporter isoforms in
normal and tumoral cells, which is tightly regulated (3, 12).
However, without the knowledge of the functional properties
of the nucleoside transporters, this issue cannot be properly
addressed. The information about the structural requirements
of the rCNT2 substrates reported in the present study compared
with hCNT2 indicates that in the case of CNT2, the rat could
be a good model for the study of particular drugs and supports
the relevance of the animal model for the study of drugs
bioavailability in vivo.
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